Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joshua S. Krumenacker is active.

Publication


Featured researches published by Joshua S. Krumenacker.


Proceedings of the National Academy of Sciences of the United States of America | 2008

Role of nitric oxide signaling components in differentiation of embryonic stem cells into myocardial cells

Kalpana Mujoo; Vladislav G. Sharin; Nathan S. Bryan; Joshua S. Krumenacker; Courtney Sloan; Shanaz Parveen; Lubov E. Nikonoff; Alexander Y. Kots; Ferid Murad

Nitric oxide (NO) is involved in number of physiological and pathological events. Our previous studies demonstrated a differential expression of NO signaling components in mouse and human ES cells. Here, we demonstrate the effect of NO donors and soluble guanylyl cyclase (sGC) activators in differentiation of ES cells into myocardial cells. Our results with mouse and human ES cells demonstrate an increase in Nkx2.5 and myosin light chain (MLC2) mRNA expression on exposure of cells to NO donors and a decrease in mRNA expression of both cardiac-specific genes with nonspecific NOS inhibitor and a concomitant increase and decrease in the mRNA levels of sGC α1 subunit. Although sGC activators alone exhibited an increase in mRNA expression of cardiac genes (MLC2 and Nkx2.5), robust inductions of mRNA and protein expression of marker genes were observed when NO donors and sGC activators were combined. Measurement of NO metabolites revealed an increase in the nitrite levels in the conditioned media and cell lysates on exposure of cells to the different concentrations of NO donors. cGMP analysis in undifferentiated stem cells revealed a lack of stimulation with NO donors. Differentiated cells however, acquired the ability to be stimulated by NO donors. Although, 3-(4-amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine (BAY 41-2272) alone was able to stimulate cGMP accumulation, the combination of NO donors and BAY 41-2272 stimulated cGMP levels more than either of the agents separately. These studies demonstrate that cGMP-mediated NO signaling plays an important role in the differentiation of ES cells into myocardial cells.


Molecular Pharmacology | 2011

Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma

Haifeng Zhu; Jessica Li; Fang Zheng; Emil Martin; Alexander Y. Kots; Joshua S. Krumenacker; Byung Kwon Choi; Ian E. McCutcheon; Norman W. Weisbrodt; Oliver Bögler; Ferid Murad; Ka Bian

The NO and cGMP signaling pathways are of broad physiological and pathological significance. We compared the NO/soluble guanylyl cyclase (sGC)/cGMP pathway in human glioma tissues and cell lines with that of healthy control samples and demonstrated that sGC expression is significantly lower in glioma preparations. Our analysis of GEO databases (National Cancer Institute) further revealed a statistically significant reduction of sGC transcript levels in human glioma specimens. On the other hand, the expression levels of particulate (membrane) guanylyl cyclases (pGC) and cGMP-specific phosphodiesterase (PDE) were intact in the glioma cells that we have tested. Pharmacologically manipulating endogenous cGMP generation in glioma cells through either stimulating pGC by ANP/BNP, or blocking PDE by 3-isobutyl-1-methylxanthine/zaprinast caused significant inhibition of proliferation and colony formation of glioma cells. Genetically restoring sGC expression also correlated inversely with glioma cells growth. Orthotopic implantation of glioma cells transfected with an active mutant form of sGC (sGCα1β1Cys105) in athymic mice increased the survival time by 4-fold over the control. Histological analysis of xenografts overexpressing α1β1Cys105 sGC revealed changes in cellular architecture that resemble the morphology of normal cells. In addition, a decrease in angiogenesis contributed to glioma inhibition by sGC/cGMP therapy. Our study proposes the new concept that suppressed expression of sGC, a key enzyme in the NO/cGMP pathway, may be associated with an aggressive course of glioma. The sGC/cGMP signaling-targeted therapy may be a favorable alternative to chemotherapy and radiotherapy for glioma and perhaps other tumors.


BMC Pharmacology | 2005

Role of nitric oxide and cyclic GMP in proliferation and differentiation of murine and human embryonic stem cells

Ferid Murad; Joshua S. Krumenacker; Mujoo Kalpana; Ks Madhusoodanan

We hypothesized that the fundamental role of nitric oxide and cyclic GMP in numerous physiological processes would suggest that these mediators also participate in stem cell proliferation and differentiation. Mouse and human (H9) embryonic stem cells were cultured under standard conditions for various periods (one to 15 days). The hanging drop method was utilized to induce differentiation of stem cells into various cellular lineages including myocardial, neuronal precursor, neuronal, astrocyte and oligodendrocytes.


Medical Science Monitor | 2001

NO, nitrotyrosine, and cyclic GMP in signal transduction.

Khalid A. Hanafy; Joshua S. Krumenacker; Ferid Murad


Brain Research Bulletin | 2004

Regulation of nitric oxide and soluble guanylyl cyclase.

Joshua S. Krumenacker; Khalid A. Hanafy; Ferid Murad


Nitric Oxide | 2006

Differential expression of genes involved in cGMP-dependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell-derived cardiomyocytes

Joshua S. Krumenacker; Shoji Katsuki; Alexander Kots; Ferid Murad


Proceedings of the National Academy of Sciences of the United States of America | 2001

Estradiol rapidly inhibits soluble guanylyl cyclase expression in rat uterus

Joshua S. Krumenacker; Salman M. Hyder; Ferid Murad


Molecular Genetics and Metabolism | 2006

NO-cGMP signaling in development and stem cells

Joshua S. Krumenacker; Ferid Murad


Proceedings of the National Academy of Sciences of the United States of America | 2000

Genomic organization of α1 and β1 subunits of the mammalian soluble guanylyl cyclase genes

Iraida Sharina; Joshua S. Krumenacker; Emil Martin; Ferid Murad


American Journal of Physiology-cell Physiology | 2005

Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase α1 gene regulation and cGMP synthesis

Joshua S. Krumenacker; Alexander Y. Kots; Ferid Murad

Collaboration


Dive into the Joshua S. Krumenacker's collaboration.

Top Co-Authors

Avatar

Ferid Murad

George Washington University

View shared research outputs
Top Co-Authors

Avatar

Emil Martin

University of Texas System

View shared research outputs
Top Co-Authors

Avatar

Alexander Y. Kots

George Washington University

View shared research outputs
Top Co-Authors

Avatar

Iraida Sharina

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Kalpana Mujoo

Houston Methodist Hospital

View shared research outputs
Top Co-Authors

Avatar

Khalid A. Hanafy

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Alexander Kots

University of Texas at Austin

View shared research outputs
Top Co-Authors

Avatar

Aurora Rachel Seminara

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Byung Kwon Choi

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Courtney Sloan

University of Texas Health Science Center at Houston

View shared research outputs
Researchain Logo
Decentralizing Knowledge